Vir Bio’s IPO Brings In $143M for Tests of Hepatitis B Drug and More

Vir Biotechnology has joined the public markets, raising $142.9 million to support clinical tests of its infectious disease drugs.

The San Francisco firm offered 7.1 million shares priced at $20 each, which was the low end of the $20 to $22 range that it had planned. Vir shares are expected to start trading later today on the Nasdaq exchange under the stock symbol “VIR.”